Methods for screening tumors for p53 status and therapeutic exploitation.
Mutations in the p53 oncosuppressor gene occur in most human cancers and regulation of the protein is defective in a variety of others. Novel strategies are emerging for the treatment of tumors that have p53 mutations. In this context, the analysis of p53 status is useful in diagnosis and prognosis, and could serve to evaluate the effectiveness of a cancer treatment. In this review, we report an overview of major methods for screening tumors for p53 status and the major strategies suggested for restoring p53 function.
Tullo
Apollonia
A
Sezione di Bioinformatica e Genomica di Bari, Istituto di Tecnologie Biomediche, CNR, via Amendola 165/A, 70126 Bari, Italy. tullo@area.ba.cnr.it
D'Erchia
Anna Maria
AM
Sbisà
Elisabetta
E
D000818:Animals; D016158:Genes, p53 / Q000235:genetics*; D005820:Genetic Testing; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D009154:Mutation; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2